What an amazing ASCO 2024 meeting highlighting a lot of lung data including possible practice changing paradiagms in early stage small cell, perioperative therapy, and EGFR patients in the post-chemoRT space.  We also have intriguing data on lung cancer screening, QoL for patients on TKI, and more!  Come join us to review the data and have some fun while doing it.  Wishing you all a great start to your summer!

5:15 - 6:15 PM

6:15 - 6:25 PM

6:25– 6:45 PM

6:45 - 7:05 PM

7:05-7:25 PM

7:25 - 7:45 PM

7:45 - 8:05 PM

8:05– 8:25 PM

8:20 - 8:30 PM

Reception & Cocktail Hour

Greetings and Introductions Dr. Nick Rohs - Mount Sinai

NYLCF updates, WCLC/ESMO 2024Thoughts

Updates on atypical EGFR mutations and HER2 Dr. Catherine Shu - Columbia

Updates on early stage/peri-definitive therapy. Dr. Isabelle Preeshagul - MSKCC

BREAK

Updates on the other drivers (ALK, MET, BRAF, etc). Dr. Christine Garcia - Cornell

Updates in classic EGFR mutations Dr. Elaine Shum - NYU

TBD Dr. Nagashree Seetharamu -Northwell

Closing Remarks Dr. Nicholas Rohs - Mount Sinai